P. Heinrich Stahl (Author/Editor) studied Pharmaceutical
Sciences in Freiburg, Germany, and completed his Ph. D. thesis on
the synthesis of purine heterocycles under the supervision of Kurt
Walter Merz. This was followed by a postdoctoral fellowship at the
Sloan-Kettering-Institute for Cancer Research, New York. In 1969,
he joined in Basel, Switzerland. At CIBA, Basel, Switzerland, he
focused his attention on pharmaceutical technology and solved
problems in tablet granulate drying. Subsequent to the merger of
the Ciba and Geigy companies, he built up the Preformulation Group
for API characterization at the interface between medicinal
chemistry, dosage form development, and analytics. After an
assignment to the Summit, N.J., research site of Ciba-Geigy, he
returned to Basel to take over the responsibility for special
formulation topics. Since 1995 he was responsible for the global
coordination of early compound evaluation. After his retirement in
1997, he still continues his research at the Biocenter in Basel,
focusing on the in vitro modeling of passive drug transport across
lipid double-layers. Dr. P. H. Stahl is an IUPAC Fellow and a
member of the International Association for Pharmaceutical
Technology, of the Pharmaceutical Society of Germany, and of the
Swiss Society of Industrial Pharmacists. He has co-authored
multiple scientific and technological papers, patents, and book
chapters. He is an active consultant to several pharmaceutical
companies.
Camille G. Wermuth (Author/Editor) PharmD, PhD, Founder,
President and Chief Scientific Officer of Prestwick Chemicalis, a
former Professor of Organic and Medicinal Chemistry at the Faculty
of Pharmacy at the Louis Pasteur University in Strasbourg, France.
Pr. Wermuth's research combines synthesis and molecular modeling,
and concentrates mainly on CNS diseases. He is the author and
co-author of over 300 peer-reviewed scientific papers and of
several books or book chapters, and holds over 60 patents. Pr.
Wermuth has been awarded the Charles Mentzer Prize of the
Société Française de Chimie Thérapeutique, the
Léon Velluz Prize of the French Academy of Science, and the
Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy.
He is Corresponding Member of the German Pharmaceutical Society,
and was nominated Commandeurs des Palmes Académiques. He has
been nominated President of the Division of Chemistry and Human
Health of the International Union of Pure and Applied Chemistry
(IUPAC).